Perampanel stumbles at first regulatory hurdle in US
This article was originally published in Scrip
The US FDA has issued a refusal to file letter for Eisai's novel epilepsy drug perampanel following a preliminary review of the data package submitted in the NDA in May.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.